Drug Trial Radar · NCT05068947
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Sep 10, 2021
Primary completion
Oct 22, 2021
Study completion Oct 22, 2021
Sponsor
- Lead sponsor
- Graviton Bioscience CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.
Conditions
- Phase 1
Interventions
GV101Drug
GV101 administered once orally.
PlaceboDrug
Matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent AEsTime frame: Up to day 7.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami
Hialeah, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.